Clinical Trial

Autologous Versus Allogeneic Hematopoietic Stem Cell Transplantation for T-Lymphoblastic Leukemia/Lymphoma in First Complete Remission

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
To evaluate, through a prospective multicenter observational study, autologous or allogeneic hematopoietic stem cell transplantation (Auto-SCT/allo-SCT)as consolidation therapy in subjects with T lymphoblastic leukemia/Lymphoblastic lymphoma(T-ALL/LBL)who have achieved first complete remission (CR). Assess relapse-free survival (RFS), overall survival (OS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM) among different treatment regimens
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-04.
Trial Details
NCT Number NCT07577531
Lead Sponsor Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Conditions T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Enrollment 84 participants
Start Date 2026-05-05
Primary Completion 2029-05-05 (estimated)
Study Completion 2029-05-05 (estimated)
Updated on ClinicalTrials.gov 2026-05-13